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ABSTRACT
Because the lung stem cell ﬁeld is so new, there remain
many unanswered questions that are being addressed
regarding the identiﬁcation, location, and role of exoge-
nous and endogenous stem and progenitor cell populations
in growth, regeneration, and repair of the lung. Advancing
lung stem cell biology will require multidisciplinary teams
and a long term effort to unravel the biologic processes of
stem cells in the lung. While no clinical research in lung
stem cell therapies are currently funded by NHLBI, the
knowledge gained by understanding the basic biology of
the lung stem cell populations will be needed to translate
to diagnostic and therapeutic strategies in the future.
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INTRODUCTION
In the new millennium, research on lung stem/progenitor cell
biology and cell-based therapies for regeneration and repair of
lung disease is of great interest not only to scientists but also
to the public. The ﬁeld of lung stem/progenitor cell biology is
in its infancy, particularly compared with studies of other
continuously renewing cell populations such as skin and gut
stem cells, and there are many opportunities for important
progress and future discovery. Our goal in writing this brief
perspective is to highlight some of the current issues and
future opportunities and challenges in the ﬁeld and to provide
information on resources and new initiatives in progenitor and
stem cell biology supported by the National Heart, Lung, and
Blood Institute (NHLBI).
Since 2001, when the grant portfolio of the NHLBI in
lung progenitor/stem cell biology consisted of less than a
handful of projects, the program has grown to almost 50 such
grants in ﬁscal year 2008 (Fig. 1). These research studies are
examining several aspects of lung stem cells such as the pluri-
potency of lung resident cells during development and after
lung injury, the impact of mesenchymal stromal cells in pre-
clinical studies of acute lung injury, and the potential to cor-
rect speciﬁc genetic defects that impact lung host defenses in
lung diseases such as cystic ﬁbrosis. Because the lung stem
cell ﬁeld is so new, there remain many unanswered questions
that are being addressed regarding the identiﬁcation, location,
and role of exogenous and endogenous stem and progenitor
cell populations in growth, regeneration, and repair of the
lung [1–5]. More than a decade ago Emura suggested ‘‘what
is urgently required is, therefore, to establish unequivocal
markers for the identiﬁcation and isolation of respiratory stem
cells’’ [6], but these markers are still undeﬁned.
Unlike the hematopoietic stem cell hierarchy, little is
known about speciﬁc cells in the lung that have the capacity
to self-renew, the organization of stem/progenitor cells in the
lung and whether it conforms to a classic or a nonclassic
stem cell hierarchy, and the differentiation pathways for the
more than 40 phenotypically and functionally distinct types of
cells that are required for air to be conducted to alveoli and
transfer of oxygen and carbon dioxide into and out of the
blood. There are at least ﬁve putative epithelial stem/progeni-
tor cell niches in the adult mouse airway [7] (Fig. 2), as well
as endothelial stem cells in the pulmonary vasculature and
airway smooth muscle stem cells. In addition, many cells
have host defense properties that are needed to protect the
lung against inhaled particles of pollutants, microorganisms,
and antigens. The human lung has 26 branches of airways
that lead to alveoli with a surface area for gas exchange of
100 m
2. Repair after injury to different regions of the lung is
expected to require different populations of stem cells for
regeneration. As airways develop, there is close proximity of
the developing pulmonary vascular system and cross-talk
between endothelial precursors and the epithelium for normal
lung development to occur [8, 9]. As with the pulmonary epi-
thelium, different cellular subpopulations of the pulmonary
endothelium probably have distinct embryonic origins.
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Lung structure programming is incredibly reproducible in the
developing mammalian embryo and fetus, which should per-
mit identiﬁcation of resident embryonic stem/progenitor cell
populations with techniques such as lineage tracing and live
imaging. Metzger et al. [10] recently demonstrated that the
airway branching process is remarkably stereotyped during
prenatal development. The airway tree is established using
Figure 1. Number of National Heart,
Lung, and Blood Institute-supported grants
in lung stem/progenitor cell biology (2001-
2008). New refers to new applications
(type 1 or 2) to the NIH. Abbreviation:
DLD, Division of Lung Diseases.
Figure 2. Illustration of putative stem
cell niches in the adult mouse lung. Epithe-
lia of the adult mouse lung can be divided
into four major, biologically distinct trophic
units (trachea, bronchi, bronchioles, and
alveoli), each of which encompasses unique
types of airway epithelial cells (epithelia
relevant to each unit are shown inside
circles). Five potential stem cell niches for
these various trophic units are shown on
the right, with locations of candidate stem
cells marked by arrowheads (cells are in
red). Stem cells and niches include the fol-
lowing: 1, an unknown cell type in the
SMG ducts of the proximal trachea; 2,
basal cells in the intercartilaginous zones
of the lower trachea and bronchi (these
structures may also be associated with
innervated NEBs; 3, variant Clara cells
associated with NEBs in bronchioles; 4,
Clara cell associated with BADJ; and 5,
alveolar type II cells of the alveoli. Abbre-
viations: BADJ, bronchiolar alveolar duct
junctions; Clara
v, variant Clara cells; NEB,
neuroendocrine body; SMG, submucosal
gland. (From Liu X, Engelhardt JF. The
glandular stem/progenitor cell niche in air-
way development and repair. Proc Am
Thorac Soc 2008;5:682-688.)
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ing; domain branching, planar bifurcation, and orthogonal
bifurcation. The processes involved in postnatal lung develop-
ment of the epithelium remain to be determined. How the
stem/progenitor cells in pulmonary vascular compartments
participate in development, regeneration, and repair is still
unknown [11]. Recent ﬁndings suggest that vascular progeni-
tor cells may arise from endogenous vascular wall progeni-
tors, from circulating bone marrow derived progenitors. As
with the epithelial cells of the lung, the heterogeneity of pul-
monary endothelial cells may require a site-speciﬁc niche of
endothelial progenitors [12], or, possibly, still unknown resi-
dent endothelial progenitor cells may constitute a universal
pool of progenitor cells that lack segmental speciﬁcation.
Some molecular signals for the master regulator of lung
development are known, but the way in which they are used
to coordinate branching routines has not yet been determined.
Five key signaling molecules regulate many processes in em-
bryonic development: Wnt, ﬁbroblast growth factor (FGF),
transforming growth factor-b (TGF-b), Hedgehog, and Notch.
In many different stem cell lines these signaling components
are needed at some level and at some time to drive differen-
tiation, but it is still not known what drives speciﬁc differen-
tiation into the multiple cell types that have distinct roles in
the lung.
However, signiﬁcant information exists about key devel-
opmental signals for a normal lung to form. Expression of the
transcription factor, thyroid transcription factor 1 (Titf-1,
Ttf1, Nkx2.1), marks the lung lineage commitment in the
early embryo, even before the primordial lung bud forms off
the foregut endoderm. Genetic studies show that Titf1 is criti-
cal for the development of distal lung progenitors [13]. The
Titf1 knockout mouse forms very abnormal lungs with insufﬁ-
cient differentiation for survival [14]. Studies also have shown
a critical role for signaling by ﬁbroblast growth factors in
speciﬁcation of the lung lineage [15]. FGF10 is expressed by
lung mesenchyme and functions as a chemotactic factor dur-
ing branching morphogenesis. If overexpressed, FGF10 stabil-
izes a progenitor cell compartment and leads to metaplastic
differentiation of goblet cells [16]. In addition to maintaining
epithelial progenitor cell proliferation FGF10 also coordinates
alveolar smooth muscle cell formation and vascular develop-
ment [17]. Retinoic acid signaling plays an important role by
affecting Fgf10 expression through TGF-b, critical for expan-
sion of lung progenitors and for formation of primary lung
buds [18]. Proximal-distal patterning of the lung depends on
Wnt/b-catenin signaling and is mediated, at least in part,
through downstream regulation of N-myc, bone morphogenic
protein-4, and FGF signaling [19]. Potentiation of b-catenin
signaling leads to the arrested differentiation of immature
bronchiolar stem cells, although b-catenin is not necessary for
maintenance of the adult bronchiolar stem cell [20].
Because pulmonary vascular and distal air space growth
are highly coordinated and injury to the developing lung can
affect both processes [8], the role of endothelial progenitor
cells in a developmental disorder, bronchopulmonary dyspla-
sia (BPD), was examined by Balasubramaniam et al. [21].
Oxygen toxicity disrupts growth of vascular and alveolar
compartments, limiting the surface area available for gas
exchange, leading to BPD. Vascular endothelial growth factor
(VEGF), nitric oxide, and erythropoietin in the lung contribute
to mobilization and homing of endothelial progenitor cells
(EPCs). After hyperoxia exposure in neonatal mice, expres-
sion of VEGF, endothelial nitric oxide synthase, and erythro-
poietin receptor and the number of EPCs in the blood, bone
marrow, and lung were reduced. In contrast, EPCs increase in
adults after hyperoxia, suggesting that there are important dif-
ferences between repair responses of progenitor cells of the
developing and mature lung.
ENDOGENOUS PROGENITOR/STEM CELLS
IN THE LUNG
Unlike other epithelial tissues that undergo rapid regeneration
such as the gastrointestinal tract and skin, the lung has much
slower turnover, which has hampered the identiﬁcation of
putative lung progenitor cells along with the lack of stem/pro-
genitor cell markers and assays to identify and isolate them.
Only recently, several candidate endogenous stem or progeni-
tor cells have been identiﬁed in the trachea and lung using
models of lung injury and repair. Subsets of K-14-expressing
basal cells in the trachea [22] have the capacity for restoration
of a differentiated epithelium after injury and are distinct
from basal cells in the bronchi [23]. Scgb1a1
þ Clara cells
have the capacity to self-renew and proliferate in response to
tracheal injury but are not the main source for tracheal regen-
eration [24].
The submucosal gland ducts in the proximal airway are
suspected to contain stem cells [7]; however, little is known
about glandular stem/progenitor cells and their niche. Studies
suggest that the regenerating surface airway tracheal epithe-
lium in a naphthalene injury model arises from cells migrat-
ing from gland ducts [25]. Mouse models, although useful for
study of stem cell regulation and understanding the relation-
ship between the stem cell and its niche, have some limita-
tions for study of submucosal glands (SMGs), because the
spatial distribution of cells in the proximal airway is so dis-
similar from that in humans [7]. The ferret model may be
more suitable because the distribution of submucosal glands
in the ferret airway is much more similar to that in humans.
Submucosal gland stem cells may be important for disorders
such as asthma, chronic bronchitis, and cystic ﬁbrosis, which
are characterized by hypertrophy and hyperplasia of SMGs.
There is a mixed population of pluripotent cells in the
lower respiratory tract that are characterized as Hoechst dye-
efﬂuxing side population (SP) cells and express molecular
markers of airway and mesenchymal origin [26]. CD45
  SP
cells isolated from human tracheobronchial epithelium have
proliferative potential. Increased numbers of these cells in
asthmatic airways suggest that dysregulation of pluripotent
cells may play a role in the pathogenesis of this chronic disor-
der [27]. In the developing lung, some of these SP cells,
which are CD45
þ and CD45
 , have endothelial progenitor
cell potential to respond to hyperoxic exposure [28].
Kim et al. [29] identiﬁed a population of endogenous cells
in the adult distal lung that have stem cell characteristics and
coined the term bronchoalveolar stem cells (BASCs). The
BASCs are resistant to naphthalene injury and proliferate in
response to airway or alveolar injury. BASCs reside near
bronchiolar-alveolar junctions, presumed stem cell niches.
The BASCs were originally deﬁned by expression of both
CC10 and SP-C, as well as coexpression of Sca-1 and, and
are capable of self-renewal and differentiation into Clara cells
and alveolar cells. Hong et al. [30] identiﬁed the variant Clara
cell as an endogenous lung stem cell, which expresses Clara
cell secretory protein and survives naphthalene injury, unlike
the more abundant progenitor Clara cell. These variant Clara
cells infrequently proliferate during steady state but are felt to
be responsible for repopulating the distal airway epithelium in
response to injury. Reynolds et al. [31] suggested that the
adult lung does not behave in a manner similar to that of
blood and other organ systems that have a classic stem cell
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with injury that is stem cell-independent (i.e., responds by
cell proliferation, similar to the liver) using transit-amplifying
progenitor cells.
The lung microcirculation is enriched in progenitor cells,
but our understanding of these cells and their interrelation-
ships is very limited. Que et al. [32] recently reported that the
mesothelium overlying the lung has a progenitor population
that gives rise to pulmonary vascular (but not epithelial)
smooth muscle cells during embryonic development. As sug-
gested by Stevens et al. [11], studies are needed to deﬁne the
biochemical and functional phenotypes of not only the pulmo-
nary endothelial cell but also smooth muscle cells that might
exist at different locations in the pulmonary vasculature.
Exploring endothelial cell populations and their functions in
homeostasis and after injury will be an important research
focus in coming years. It is not known whether
the pulmonary vascular wall contains resident smooth muscle
cell progenitors, nor is it known whether circulating bone
marrow-derived progenitor cells have a role in mediating lung
vascular repair or remodeling.
REPROGRAMMING STEM CELLS (INDUCED
PLURIPOTENT STEM AND EMBRYONIC)
The use of embryonic and induced pluripotent stem (iPS)
cells to regenerate solid organs has great potential, but has
not been well studied in lung. Further study using both pluri-
potent stem cell strategies is needed. A respiratory epithelium
has been developed using mouse embryonic stem (ES) cells
cultured as embryonic bodies with speciﬁc growth hormones
in an air-liquid interface [33], and mouse ES cells in appro-
priate culture conditions can express cell markers of alveolar
type II cell differentiation [34]; however, it is unclear whether
these reprogrammed cells have functional potential. Applica-
tion of murine ES models using human tissue is limited by
ethical and technical challenges. Recent reports of the use of
somatic cells dedifferentiated to embryonic-like cells raise the
possibility of creating organ-speciﬁc autologous stem cells for
therapy. Caution exists, however, because the dedifferentia-
tion of these cells also makes them tumorigenic. Perhaps
directing cell reprogramming without reversion to a pluripo-
tent stem cell state of one lung cell type into another using
deﬁned factors to reconstitute the airway epithelium will be
another strategy as has been accomplished for the pancreas
[35]. Human amniotic ﬂuid has recently been shown to con-
tain a new source of stem cells that can be differentiated into
lung epithelial cell lineages [36]. It is still not known whether
‘‘conversion’’ is restricted to gene and/or marker expression
rather than functional potential. It should also be pointed out
that differentiation of such cell populations into lung lineages
in vivo (where measured) is generally minimal. Unfortunately,
little is known about the appropriate signals to direct differen-
tiation of multipotent stem/progenitor cells into respiratory
epithelium and endothelium and to program cells to bioengi-
neer an organized, complex, functional structure of the lung.
Three-dimensional tissue engineering technologies may offer
new strategies for investigating lung progenitor/stem cell
interactions and function.
Repair/Regenerative Capacity
Whereas turnover of the respiratory epithelium in the steady
state is very slow, it has signiﬁcant reparative capability after
injury. The lung is exposed to many environmental irritants
that can induce inﬂammation and injury. If the host response
is appropriately controlled, local repair of the epithelium is
possible. The lung ﬁlters 8,000-9,000 liters of air each day.
When gas is exchanged, the respiratory epithelium must
defend itself against irritants such as viral particles, tobacco
smoke, pollutants, and aspirated food particles.
Endogenous stem cells probably play an important role in
repair after injury, and depending on the compartment of the
tracheobronchial tree that is injured, there will probably be
different strategies for repair: basal cells in the trachea, vari-
ant Clara cells or BASCs in the bronchioles, and alveolar
type II cells in the air sacs. One strategy for lung repair may
include identifying molecules that can stimulate endogenous
stem cell responses. Activation of canonical Wnt signaling in
the niche containing BASCs can signiﬁcantly increase the
pool of stem cells [34]. Gata6 is required for these stem
cells to differentiate and regenerate the respiratory epithelium.
b-Catenin signaling in the developing lung attenuates stem
cell differentiation, increasing self-renewal of the stem cell
population [31]. An understanding of the controlled differen-
tiation into functional respiratory epithelial cell populations to
carry out gas exchange and airway defense will also need to
be considered in strategies that attempt to harness the regener-
ative capacity of the endogenous stem cell. In addition, bone
marrow-derived mesenchymal stem cells (MSCs) show prom-
ise and have been used to ameliorate lung injury in several
models of lung disease. Although MSCs have stem cell prop-
erties and differentiation potential, the functional improve-
ments seen in models of MSC therapy for lung injury, does
not require engraftment or differentiation, suggesting that
anti-immune, anti-inﬂammatory cytokine modulation, and/or
stimulation of endogenous progenitor/stem cells are involved
[37–39].
The report of a workshop on lung stem cell biology and
disease, cosponsored by the NHLBI and the Cystic Fibrosis
Foundation, is another excellent resource for information on
current knowledge and controversies regarding lung stem/
progenitor cells, including the potential therapeutic role of
adult bone marrow-derived stromal cells in lung diseases
[4]. Manipulating the apparent reparative functions of these
cells is an area of keen research interest. Disorders such as
cystic ﬁbrosis involving defects in ion transport of airway
epithelial cells, obstruction, and epithelial injury from recur-
rent infection, could be repaired with gene replacement
using bone marrow stem cells. It is not clear whether the
very low engraftment rates [40] will be sufﬁcient to correct
cystic ﬁbrosis ion transport defects that contribute to
impaired host defense and decrease the frequency of bron-
chopneumonias that ultimately lead to lung destruction and
respiratory failure.
Injury to the alveolar compartment and aberrant repair
contribute to the pathogenesis of idiopathic pulmonary ﬁbro-
sis. Alveolar type I cells (AECI) cover 96% of the gas
exchange surface area of the lung and are very fragile because
of their very thin structure. Alveolar type II cells (AECII) that
occupy only 4% of the gas exchange surface are thought to
be responsible for alveolar type I cell regeneration after
injury. It is not clear whether all alveolar type II cells can
regenerate themselves and the AECI after injury or if only a
subpopulation of AECII have this reparative capacity. In bone
marrow transplant protocols when the alveolar compartment
is severely damaged, donor hematopoietic stem cells (HSCs)
have been found in the recipient lung, suggesting that the
HSCs might contribute to proliferation of alveolar epithelial
cells [41–43]. This ﬁnding has been refuted by Kotton et al.
[44] as an artifact of autoﬂuorescence. Idiopathic pulmonary
ﬁbrosis may be due to abnormal repair of the alveolar com-
partment and include the abnormal recruitment of bone
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using stem cells for the treatment of lung diseases have not
yet established safety and efﬁcacy.
Osiris Therapeutics, Inc. currently has one product, Pro-
chymal, an intravenously administered formulation of mesen-
chymal stem cells, in a phase II clinical trial for the repair of
lung tissue in patients with moderate to severe chronic
obstructive pulmonary disease (http://www.osiristx.com/
clinical_trials_prochymal_copd.php). Results from this trial on
safety and efﬁcacy endpoints at 2 years in subjects with
COPD have not yet been reported.
The complex structure and multiple functions of the lung
compartments leave many unanswered questions in lung stem
cell biology for the treatment of human diseases.
GAPS
The molecular proﬁle of the multipotent progenitor cells that
reside at the various germ layers and regions of the lung as
the respiratory tract forms is largely unknown [46]. Identiﬁca-
tion of stem cell compartments, responsible for repair of tra-
cheal, bronchial, bronchiolar, and alveolar epithelium will be
important. The endothelial progenitors and signals for their
interaction with mesenchymal and epithelial tissue to permit
reconstitution of an air exchange unit have not yet been deter-
mined. Although some speciﬁc molecular signals that are
required to retain a stem cell niche have recently been identi-
ﬁed, what signals exist in the steady state versus after injury
need to be further elucidated. In addition, the molecular sig-
nals that permit repopulation of the epithelium and differen-
tiation to speciﬁc lung cells with appropriate functional prop-
erties need to be further understood.
There are many questions that would be important to
answer regarding lung stem/progenitor cell biology: What is
the role of HSCs or MSCs in lung repair/regeneration and is
engraftment necessary? Are there circulating factors and other
mechanisms that induce endogenous progenitor cells to
respond? Can the potential harmful effects of exogenous stem
cell therapy be minimized to permit restoration of lung tissue?
What are the signals released by the injured or remodeling
lung that mobilize and attract bone marrow-derived stem cells
to the site of injury? Can embryonic or induced pluripotent
stem cells be programmed to reconstitute a functioning lung
unit? How do cytokines and growth factors inﬂuence the
function of stem cells and their progeny in acute and chronic
lung disease? What are the biochemical and functional pheno-
types of pulmonary endothelial and smooth muscle progenitor
cells? What is the role of endothelial progenitor cells in vas-
cular development, homeostasis, and repair after vascular
injury? What role do these cells play in vascular disease?
Very limited research in tissue engineering of the lung is
currently funded at NHLBI. In the short term tissue engineering
may be used to enhance drug testing by developing three-
dimensional in vitro models of disease that more closely reﬂect
the in vivo state than current two-dimensional cell culture sys-
tems. Regenerative therapeutics to replace a large airway in a
human has recently been demonstrated [47], but building a
functional lung unit to replace defective lung tissue or lost lung
tissue will require a longer time frame and multidisciplinary
collaborations. Selection of the ideal cell source, strategies for
optimal cell isolation, identiﬁcation of a biocompatible and
degradable scaffold, and choice of cell culture conditions and
growth factors needed to direct differentiation of the diverse
cell types are several aspects that remain to be determined.
OPPORTUNITIES FOR RESEARCH SUPPORT
The NHLBI has a strong interest in supporting stem cell
research and has encouraged growth in this area with several
new Requests for Applications (RFAs) offered in 2007-2009
(Table 1). These RFAs support the goals of the NHLBI strate-
gic plan, which highlights the goals of improving understand-
ing of the molecular and physiologic basis of health and
disease and developing personalized preventive and therapeu-
tic regimens for cardiovascular, lung, and blood diseases [48].
Integrating advances in stem cell biology and regenerative
medicine to develop clinically feasible applications is a long-
term goal the NHLBI is working toward reaching in the
future. Examples of past and current programs in heart, lung,
and blood diseases are presented in Table 1 as well as resour-
ces for investigators.
At present, there are a number of promising discoveries,
technologies, and reagents that are poised to have a catalytic
effect on the ﬁeld of regenerative biology and medicine: the
ability to constitute pluripotent stem cells from reprogramming
with speciﬁc transcription factors using integrating viruses,
nonintegrating viruses [49], or recombinant proteins [50]; and
lineage tracing with Cre recombinase models [24, 32], imaging
of live cells [51], and markers of lung stem/progenitor cells
[24, 29, 52]. In 2008-2009, NHLBI issued an RFA ‘‘NHLBI
Progenitor Cell Biology Consortium.’’ The aim of this initia-
tive is to markedly accelerate progress by forming a coordi-
nated consortium that includes leading scientists in the ﬁeld of
cardiovascular, pulmonary, and hematopoietic cell biology,
working closely with experts in the general ﬁeld of progenitor
cell biology. The goal of the consortium will be to harness
advances in stem and progenitor cell biology to improve the
understanding and treatment of cardiovascular, lung, and blood
diseases. Areas of emphasis are expected to include lineages
derived from murine and human embryonic stem cells, pro-
genitor cells, somatic stem cells, and iPS cells. In addition, the
derivation of iPS cells from patients with genetic diseases and
differentiation of these cells to speciﬁc cell types are expected
to give unique mechanistic insight into disease processes.
NHLBI recognizes that fundamental knowledge of pulmo-
nary stem and progenitor cell biology, including progenitor
cell lineages, lags behind the level of understanding in the
cardiovascular and hematopoietic ﬁelds and has supported sci-
entiﬁc meetings for lung stem cell biology and targeted funds
through RFA mechanisms to support this new ﬁeld (Table 1).
An area of emphasis in recent initiatives is the generation of
well-characterized lung progenitor cell fate maps, integrated
with speciﬁc approaches to identify, purify, renew, and direct
the differentiation of speciﬁc lineages of interest. Another im-
portant focus will be regional and/or developmental differen-
ces in cell origin and lineage, the identiﬁcation of appropriate
phenotypic markers to facilitate these studies, and program-
ming and regeneration of three-dimensional structures for gas
exchange and host defense. Research support of investigator-
initiated and/or targeted RFAs is expected to foster innovative
new technologies, reagents, strategies, and protocols that will
have a major impact on scientiﬁc, translational, and clinical
utility of lung progenitor cell lineages.
Investigators are encouraged to pursue careers in this
exciting new area of lung biology that presents many opportu-
nities for advancing the understanding of lung health and dis-
ease and developing new strategies for treatment (Table 2).
We encourage investigators to contact staff, who can answer
questions about NIH-supported research and review the
NHLBI strategic plan [48]. Advancing lung stem cell biology
will require multidisciplinary teams and a long-term effort to
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Although no clinical research in lung stem cell therapies is
currently funded by NHLBI, the knowledge gained by under-
standing the basic biology of the lung stem cell populations
will be needed to translate to diagnostic and therapeutic strat-
egies in the future. Several studies are being conducted out-
side the United States using cell therapy to treat lung disor-
ders [5]. It will be important to be prudent, rigorous, and
careful as researchers in the United States proceed in transla-
tional science in lung stem cell therapies. Early interactions
with the Food and Drug Administration are encouraged to put
in place the appropriate studies for investigational new drug
and device applications.
TRAINING
Preparing and training scientists in lung stem/progenitor cell
biology will be important to accelerating the ﬁeld. NHLBI sup-
ports multidisciplinary training of postdoctoral fellows through
training grants and supports funding of educational symposia
on fundamental stem cell biology at society meetings [5]. We
encourage today’s stem cell experts to identify promising Ph.D.
and M.D. candidates and mentor their scientiﬁc careers. The
T32 and F32 support mechanisms from NHLBI have supported
many young investigators in pulmonary research, which often
has led to the K series of awards for postdoctoral trainees. The
Table 2. Research opportunities for lung stem/progenitor cell research
1. Identify and isolate putative stem cells with improved reagents that can be used for cell sorting.
2. Develop functional assays of ‘‘stemness’’ of lung cells.
3. Develop genetic tools to follow cell fate and lineage relationships both in the embryo and the adult.
4. Determine the molecular signals that instruct the lung stem/progenitor cells to differentiate.
5. Determine how endothelial and stromal cell populations interact with the epithelium to regenerate lung tissue after injury or resection.
6. Examine the role of hematopoietic stem cells or mesenchymal stem cells in lung repair/regeneration, and determine whether engraftment is
necessary or are there paracrine factors and other mechanisms that induce endogenous progenitor cells to respond?
7. Discover the signals released by the injured or remodeling lung that mobilize and attract bone marrow-derived stem cells to the site of
injury.
8. Develop reprogramming strategies of embryonic or induced pluripotent stem cells to reconstitute a functioning lung unit.
9. Identify the cytokines and growth factors that inﬂuence the function of stem cells and their progeny in repair after acute and chronic lung
injury.
10. Identify the biochemical and functional phenotypes of pulmonary endothelial and smooth muscle progenitor cells.
11. Ascertain the role of endothelial progenitor cells in vascular development, homeostasis, and repair after vascular injury.
12. Establish the ideal properties of a biocompatible and degradable scaffold.
Table 1. NHLBI/NIH supported stem cell initiatives
Current NHLBI stem cell initiatives
NHLBI Patient Oriented and Career Enhancement Award for Stem Cell Research (K18) (Established Researchers), http://www.nhlbi.
nih.gov/funding/training/redbook/k18est-junior.htm
NHLBI Progenitor Cell Biology Consortium (R01): RFA-HL-09-004 (limited competition)
Recent NHLBI stem cell initiatives
American Recovery and Reinvestment Act of 2009
NHLBI Participation in NIH Challenge Grants in Health and Science Research (RFA-OD-09-003)
Challenge ideas:
06-HL-109_Generate reagents for studying lung cell biology and disease progression.
11-HL-101*_Develop cell-based therapies for cardiovascular, lung, and blood diseases.
14-HL-101*_Develop molecular signatures for heart, vascular, lung, and blood diseases by proﬁling reprogrammed induced pluripotent
stem cells derived from affected individuals of deﬁned genotype.
NHLBI Participation in Research and Research Infrastructure ‘‘Grand Opportunities’’ (RC2) (RFA-OD-09-004)
Grand opportunities:
Characterizing differentiated heart, lung, and blood cells derived by reprogramming human embryonic and induced pluripotent stem
cells.
Collaborative Studies on Lung Stem Cell Biology and Cell Based Therapy (RFA HL07-003), http://grants.nih.gov/grants/guide/rfa-ﬁles/
RFA-HL-07-003.html (RFA closed)
CV Cell Therapy Research Network (CCTRN) (RFA HL06-001), http://grants.nih.gov/grants/guide/rfa-ﬁles/RFA-HL-06-001.html
Network of 4 centers and 1 data coordinating center to conduct phase I and phase II clinical projects (RFA closed)
Innovative Cellular Therapies and Methods at GMP Cell Therapy Facilities: 2 day workshop held in Pittsburgh, May 5-6, 2008 (PACT
education program)
Specialized Centers for Cell-Based Therapy (SSCT) (RFA HL04-017), http://grants.nih.gov/grants/guide/rfa-ﬁles/RFA-HL-04-017.html:
network of 3 specialized centers and 1 DCC; each center conducts preclinical and 2 clinical research projects (RFA closed)
Directed Stem Cell Differentiation for Cell Based Therapies for Heart, Lung, Blood, and Aging Diseases, Expiration Date: September 8,
2008; PA-06-124 (SBIR [R43/R44]; http://grants.nih.gov/grants/guide/pa-ﬁles/PA-06-124.html) and PA-06-125 (STTR [R41/R42];
http://grants.nih.gov/grants/guide/pa-ﬁles/PA-06-125.html)
NIH Stem Cell Initiatives
Human Pluripotent Stem Cell (hPSC) Research using Non-Embryonic Sources (R01 and R21), Expiration Date: January 8, 2011;
PA-08-043 (R01; http://grants.nih.gov/grants/guide/pa-ﬁles/PA-08-043.html) and PA-08-044 (R21; http://grants.nih.gov/grants/guide/
pa-ﬁles/PA-08-044.html)
Novel Approaches to Enhance Animal Stem Cell Research (R01), Expiration Date: January 8, 2010 (PA-07 303, http://grants.nih.gov/
grants/guide/pa-ﬁles/PA-07-303.html)
Abbreviations: NHLBI, National Heart, Lung, and Blood Institute; RFA, Request for Application.
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investigators to acquire new research capabilities in the use of
human or animal embryonic, adult, or cord blood stem cells
(Table 1). This K18 award was speciﬁcally developed for can-
didates who have a clinical or research doctoral degree and are
actively engaged in research of interest to the NHLBI. All can-
didates must have a sponsor, either within their own or at
another institution, who is a well-qualiﬁed stem cell expert and
will serve as a mentor.
There are >500 fellows in Pulmonary and Critical Care
Medicine training programs [53]. A pipeline of pulmonary
clinicians will be needed to prepare for the ultimate goal of
regenerative medicine for a multitude of lung disorders of
inadequate growth (bronchopulmonary dysplasia and congeni-
tal malformations) and injury (asthma, cystic ﬁbrosis, acute
lung injury, pulmonary ﬁbrosis, and emphysema, and others).
RESOURCES
The Production Assistance for Cellular Therapies (PACT)
program supported by NHLBI was designed to develop novel
somatic cellular therapies that will aid investigators by pro-
viding support in areas ranging from basic science through
animal studies to proof-of-principle and eventually human
clinical trials (Table 2). The cell-processing facilities provide
the cellular product requested by an investigator along with
the assurance that it is of clinical grade and is produced in a
manner compliant with all regulatory requirements. In addi-
tion to product manufacture, PACT provides technical and
regulatory expertise and educational programs. The Human
Cell Therapy program provides Good Manufacturing Practice-
grade cell resources to facilitate the development of new cell
therapy. For additional information on NHLBI resources for
cell-based therapy, see the editorial by John W. Thomas [54].
For those interested in reprogramming strategies for lung
regeneration, human embryonic cells that are approved for
NIH supported research are available through the National
Embryonic Stem Cell Bank (Table 3). NIH supported investi-
gators who propose to use human embryonic stem cells must
comply with NIH policy, which is being revised and will be
issued later this year.
DISCLOSURE OF POTENTIAL CONFLICTS
OF INTEREST
The authors indicate no potential conﬂicts of interest.
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